MDNC Medinotec Inc.
Surgical & Medical Instruments & Apparatus · OTC · SEC CIK 1931055 · Fiscal year ends 02/28
Financial factors as of 2026-08-31 (2027Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY-10.9%
TTM net income YoY-73.4%
TTM EPS YoY-73.4%
Revenue 3-yr CAGR92.4%
Net income 3-yr CAGR—
Margins
Gross margin49.6%
Operating margin6.6%
Net margin5.8%
FCF margin—
EBITDA margin7.6%
Returns
ROE11.1%
ROA9.0%
ROIC (approx.)22.6%
Asset turnover1.53x
Leverage & solvency
Liabilities / assets14.7%
Debt / equity0.00x
Current ratio6.74x
Interest coverage21.76x
Cash quality & payout
Operating cash flow / net income0.63x
Accruals ratio3.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2027Q22026-08-31 | 2027Q12026-05-31 | 2026Q4*2026-02-28 | 2026Q32025-11-30 | 2026Q22025-08-31 | 2026Q12025-05-31 | 2025Q4*2025-02-28 | 2025Q32024-11-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $3.20M | $2.65M | $1.82M | $2.54M | $3.24M | $2.13M | $3.53M | $2.57M |
| Cost of revenue | $1.64M | $1.34M | $967,581 | $1.19M | $1.25M | $1.22M | -$7.37M | $1.52M |
| Gross profit | $1.56M | $1.31M | $854,557 | $1.35M | $1.98M | $913,168 | $2.39M | $1.04M |
| R&D expense | $22,076 | $7,970 | $26,283 | $8,326 | $66,235 | $49,014 | -$177,275 | $69,270 |
| SG&A expense | $835,893 | $594,286 | $586,781 | $435,395 | $706,597 | $557,418 | -$2.40M | $379,217 |
| Operating income | $202,723 | $180,872 | -$264,222 | $552,712 | $528,565 | $277,457 | $1.96M | $527,451 |
| Interest expense | $8,620 | $6,868 | $8,280 | $7,116 | $40,274 | $31,925 | $27,909 | $43,400 |
| Pretax income | $180,243 | $208,499 | -$273,121 | $542,714 | $536,822 | $262,772 | $1.92M | $481,474 |
| Income tax | $139,377 | — | -$753,232 | $13,515 | $190,256 | $148,988 | -$1.28M | $148,988 |
| Net income | $40,866 | $222,014 | -$69,259 | $403,411 | $346,566 | $113,784 | $1.48M | $310,311 |
| EBITDA | $224,547 | $202,154 | -$206,018 | $560,378 | $536,062 | $284,963 | $1.96M | $546,657 |
| EPS (basic) | 0.00 | 0.02 | — | 0.03 | 0.03 | 0.01 | — | 0.03 |
| EPS (diluted) | 0.00 | — | — | — | 0.03 | 0.01 | — | — |
| Weighted avg. shares (diluted) | 11.76M | — | — | — | 11.75M | — | — | — |
| Balance sheet | ||||||||
| Cash & equivalents | $2.58M | $2.52M | $2.76M | $2.86M | $2.25M | $1.95M | $2.77M | $2.68M |
| Receivables | $2.62M | $2.51M | $2.35M | $2.26M | $2.58M | $3.89M | $2.61M | $992,464 |
| Inventory | $1.15M | $1.43M | $1.24M | $1.21M | $994,074 | $928,070 | $988,341 | $1.15M |
| Current assets | $6.44M | $6.57M | $6.42M | $6.47M | $5.98M | $6.96M | $6.42M | $4.92M |
| PP&E, net | $374,808 | $345,011 | $331,346 | $325,916 | $333,296 | $344,653 | $348,486 | $378,294 |
| Total assets | $6.95M | $6.99M | $6.81M | $6.85M | $6.37M | $7.40M | $6.81M | $5.36M |
| Current liabilities | $955,281 | $1.13M | $1.10M | $1.35M | $1.53M | $2.09M | $1.51M | $1.47M |
| Total liabilities | $1.02M | $1.13M | $1.10M | $1.35M | $1.53M | $3.04M | $2.54M | $2.54M |
| Shareholders' equity | $5.93M | $5.85M | $5.71M | $5.50M | $4.84M | $4.37M | $4.27M | $2.83M |
| Shares outstanding | 11.76M | 11.76M | 11.76M | 11.76M | 11.76M | 11.76M | 11.73M | 11.73M |
| Cash flow statement | ||||||||
| Operating cash flow | $107,526 | -$176,125 | -$120,641 | $563,139 | $1.22M | -$759,238 | $98,715 | $124,510 |
| Capital expenditure | $46,635 | $40,350 | — | — | — | — | -$1,346 | $72,626 |
| Free cash flow | $60,891 | -$216,475 | — | — | — | — | $100,061 | $51,884 |
| Investing cash flow | -$46,635 | -$40,350 | — | — | — | — | $1,346 | -$72,626 |
| Financing cash flow | — | — | $25 | -$2,531 | -$942,567 | -$37,900 | -$50,927 | -$109,684 |
| Depreciation & amortization | $21,824 | $21,282 | $58,204 | $7,666 | $7,497 | $7,506 | -$657 | $19,206 |
Free plan shows the latest 8 periods; Pro shows all 21 🔒
· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.